Urokinase-type plasminogen activator (uPA) is a protease involved in the process of tissue remodelling and cell migration in vitro. To explore whether uPA is a prerequisite for human ovarian cancer spread in vivo the expression of uPA was suppressed in human ovarian cancer cells by antisense phosphorothioate oligonucleotides (PS-ODN). The suppression of uPA expression was dependent on PS-ODN concentration and only observed in the presence of liposomes. This phenomenon seemed to be due to the fact that PS-ODNs were taken up by the cancer cells only in concert with liposomes as studied by fluorescently-labeled PS-ODNs using flow cytofluorometry and laser scanning microscopy. uPA-deprived cancer cells exhibited a significantly reduced invasive capacity in vitro compared with untreated cancer cells or cells treated with control PS-ODNs (P = 0.003). The intraperitoneal spread of the cancer cells in vivo was significantly diminished when nude mice were treated with uPA antisense PS-ODNs in comparison with control mice (P = 0.009). These results suggest that uPA expression may be required for spread of human ovarian cancer and that its inhibition could provide a therapeutic approach.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wilhelm, O, Hafter, R, Coppenrath, E, et al. 1988, Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res, 48, 3507–14.
Hafter, R, Klaubert, W, Gollwitzer, R, von Hugo, R and Graeff, H, 1984, Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res, 35, 53–64.
Dane, K, Andreasen, PA, Grondahl-Hansen, J et al. 1985, Plasminogen activators, tissue degradation and cancer. Adu Cancer Res, 44, 139–266.
Wilhelm, O, Hafter, R, Henschen, A, Schmitt, M and Graeff, H, 1990, Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood, 75, 1673–8.
Astedt, B and Holmberg, L, 1976, Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature, 262, 595–5.
Kuhn, W, Pache, L, Schmalfeldt, B, et al. 1995, Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol, 55, 401–9.
Jänicke, F, Schmitt, M, Pache, L, et al. 1993, Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 24, 195–208.
Nekarda, H, Siewert, JR, Schmitt, M and Ulm, K, 1994, Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet, 343, 117.
Schmitt, M, Jänicke, F and Graeff, H, 1992, Tumor-associated proteases. Fibrinolysis, 6, 3–26.
Blasi, F, 1988, Surface receptors for urokinase plasminogen activator. Fibrinolysis, 2, 73–84.
Plow, EF, Freaney, DE, Plescia, J and Miles, LA, 1986, The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol, 103, 2411–20.
Stetler-Stevenson, WG, Liotta, LA and Kleiner, DE, 1993, Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J, 7,1434–41.
Kirchheimer, J, Christ, G and Binder, B, 1989, Growth stimulation of human epidermal cells by urokinase is restricted to the intact enzyme. Eur J Biochem, 181, 103–7.
Berdel, WE, Wilhelm, O, Schmitt, M, et al. 1993, Urokinase-type plasminogen activator (uPA), a protease with cytokine-like activity in human HL-60 leukemic cells. Int J Oncol, 3, 607–13.
Dumler, I, Petri, T and Schleuning, WD, 1993, Interaction of urokinase-type plasminogen activator (uPA) induces phosphorylation of a 38 kDa protein. FEBS Lett, 322, 37–40.
Cajot, JF, Schleuning, WD, Medcalf, RL, et al. 1989, Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J Cell Biol, 109, 915–25.
Yu, H and Schultz, R, 1990, Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res, 50, 7623–33.
Ossowski, L and Reich, E, 1983, Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35, 611–9.
Kobayashi, H, Ohi, H, Shinohara, HS, et al. 1993, Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membrane invasion. Br J Cancer, 67, 537–44.
Wilhelm, O, Weidle, U, Höhl, S, et al. 1994, Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA): inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett, 337, 131–4.
Ossowski, L, Russo-Payne, H and Wilson, WL, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in nude mice. Cancer Res, 51, 274–81.
Wilhelm O, Schmitt M, Senekowitsch R, et al. 1994, The urokinase/urokinase receptor system — a new target for cancer therapy? In Prospects in Diagnosis and Treatment of Breast Cancer, Elsevier Excerpta Medica International Congress Series 1050, pp. 145–56.
Kobayashi, H, Gotoh, J, Shinohara, H, Moniwa, N and Terao, T, 1994, Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemostat, 71, 474–80.
Hearing, V, Law, L, Corti, A, Appella, E and Blasi, F, 1988, Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res, 48, 1270–8.
Crowley, CW, Cohen, RL, Lucas, BK, et al. 1993, Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci, USA, 90, 5021–5.
Möbus, V, Gerharz, CD, Press, U, et al. 1992, Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian cancer cell lines. Int J Cancer, 52, 76–84.
Meissauer, A, Kramer, MD, Schirrmacher, V and Brunner, G, 1991, Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res, 192, 453–9.
Will, C, Wilhelm, O, Höhl, S, et al. 1994, Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human ovarian cancer cells and in vitro invasion capacity. Int J Oncol, 5, 753–61.
Stein, CA and Cheng, YC, 1993, Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science, 261, 1004–12.
Mignatti, P, Robbins, E and Rifkin, DB, 1986, Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47, 487–98.
Towle, M, Lee, A, Maduakor, E, et al. 1993, Inhibition of urokinase by 4-substituted benzo[b]thiophene-2carboxamidines: an important new class of selective urokinase inhibitors. Cancer Res, 53, 2553–9.
32. Kook, Y, Adamski, J, Zelent, A and Ossowski, L, 1994, The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J, 13, 3983–91.
Kitajima, I., Shinohara, T, Bilakovics, J, et al. 1992, Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-κB. Science, 258, 1792–5.
Carmeliet, P, Schoonjans, L, Kieckens, L, et al. 1994, Physiological consequences of loss of plasminogen activator gene function in mice. Nature, 368, 419–24.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilhelm, O., Schmitt, M., Höhl, S. et al. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metast 13, 296–302 (1995). https://doi.org/10.1007/BF00133485
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00133485